Scinai Immunotherapeutics has completed a strategic corporate reorganization that establishes a dedicated contract development and manufacturing organization (CDMO) subsidiary and a leaner research and development operation.
The restructuring follows Scinai’s February acquisition of Recipharm Israel Ltd., renamed Scinai Biopharma Services Ltd., which includes a small-molecule development and manufacturing facility in Yavne. Under the updated structure, all CDMO-related assets, employees, contracts, and infrastructure have been transferred into Scinai Biopharma Services, which now operates as a wholly owned, privately held subsidiary focused exclusively on CDMO activities.
The separation creates two distinct business units: Scinai Biopharma Services, which manages the company’s manufacturing operations, and Scinai Immunotherapeutics, which continues R&D work on inflammation and immunology therapeutics. Scinai said the change is intended to improve capital efficiency, streamline operations, and give each unit clearer strategic focus.
The CDMO platform is built around three components: a biologics and aseptic manufacturing site in Jerusalem, the small-molecule and API facility in Yavne, and a commercial collaboration with Recipharm that grants access to extended production capacity through structured subcontracting and network agreements.
Scinai Immunotherapeutics now operates with a smaller R&D organization aimed at advancing select pipeline programs while reducing overhead and redirecting non-core functions to the CDMO business. The company said the new structure positions both operations to pursue growth independently while maintaining shared ownership and alignment under the Scinai group.